Followers
0
Following
0
Blog Posts
5
Threads
34
Blogs
Threads
Portfolio
Follower
Following
2024-04-13 22:00 | Report Abuse
hard disk shortage and price increase is real
2020-10-09 18:45 | Report Abuse
nais deep dive. appreciate it
2020-08-09 11:19 | Report Abuse
Time DotCom
Assuming the Company is able to generate 10-15% growth consistently over the years and couple with the continuous cash generation as per % of sales, with an average industry PE of 20 (conservative PE) the company could derive a fair value of RM 14.97 which is 37-38% upside from their current share price.
https://jawplace.com/the-growth-of-data-usage/
2020-06-09 17:56 | Report Abuse
Careplus (investor briefing)
Turnover could easily exceed RM500 mil with current facility back to 90% utilisaton (in 2019 disrupted by plant modifications and changes for improvement) compared to 83% for FY 2019 (88% FY 2018) and the ASP increase could easily exceed 20% compared to 2019. You can buy upto price of 170.
My valuation based on PE15 to 18 using a projected ASP increase by 25% is from 223 to 267. However with a 20% increase, the valuation would be 180 to 216,
CAREPLUS
Catalyst for Investment and Investment Merits
• • Completion of disposal of 50% equity interest in Careplus (M) S/B (CMSB), a wholly owned subsidiary to Ansell for RM 27.0 mil, improving its net current liability position at 31 Dec 2019
• • Sale at 150% of the 50% Net Asset value of CMSB and realized a profit on disposal of about RM17.98mil which is about 3.07 Sen EPS in Q2 FY 2020.
• • Net proceeds of cash RM28.5 mil coming to Careplus after netting of additional share capital of RM10.5 mil for reinvestment in CMSB for subscription of new shares for expansion in CAPEX and repayment by CMSB of inter co loan of 12 mil
• Careplus’on-going structural transformation could translate into sustainable earnings growth.
• Margin expansion and improving profitability: Underpinned by high ASP (driven by COVID19 outbreak), lower raw mat cost and improved plat utilization rate
• The plant modification and improvement in FY 2019 will see plant utilization rate increased from 83% in 2019 to almost 90%
• Synergistic JV with Ansell: Leverage on Ansell’s global footprints and market leadership to sustain long term earnings growth
Careplus’s prospect has improved significantly with Ansell (world largest surgical glove brand) JV in CMSB (on a 50:50 basis) and earnings growth accelerated with increase capacity with 9 new production lines which will be commissioned by end 2020 and another 2 will be installed in 2021.
The JV will increase production capacity from 4.1 billion pcs to 5.6 bil pieces by end 2020 and 6.5 bil pieces by end of 2021 barring any interruption. A 52% increase in production capacity with 9 new production lines by 2022: Expected to add capacity by 2.2 bil pcs/year to achieve total capacity of 6.3bil pcs/year by year 2022 (4.1 bil 2019)
• Shifting to higher value product offering: Increasing production mix with higher value surgical gloves making about 30% of the total revenue compared to 5% in FY 2019
2020-06-07 00:31 | Report Abuse
Careplus’s prospect has improved significantly with Ansell (world largest surgical glove brand) partnership and earnings growth accelerated by COVID-19
Join us for a Q1FY20 result briefing to understand how Careplus’ on-going structural transformation could translate into sustainable earnings growth.
Date: 9th June 2020
Time: 10:30 AM
Venue: Microsoft Teams
Company Overview
Listed in 2010, Careplus is a latex and nitrile rubber glove specialized manufacturer based in Seremban with 4.1bil output capacity. Post-Ansell JV, Careplus will produce higher value surgical gloves.
Investment Highlights
1. Margin expansion and improving profitability: Underpinned by high ASP (driven by COVID19 outbreak), lower raw mat cost and improved plant utilization rate (from 90% in 2019 to almost 100%)
2. Synergistic JV with Ansell: Leverage on Ansell’s global footprints and market leadership to sustain long term earnings growth
3. c.52% increase in production capacity with 9 new production lines by 2022: Expected to add capacity by 2.2 bil pcs/year to achieve total capacity of 6.3bil pcs/year by year 2022 (4.1 bil 2019A)
4. Shifting to higher value product offering: Increasing production mix with higher value surgical gloves
RSVP latest by 5th June 2020, Friday and we will send you a link to participate in the Conference Call. Seats are limited!
Thanks.
2020-06-07 00:30 | Report Abuse
Rocket d careplus. Investor briefing my the MD on Tuesday. First investor briefing. If its not good why got briefing?
2020-06-01 21:05 | Report Abuse
Yes. thanks for confirmation. hope can collect more tomorrow.
2020-06-01 18:59 | Report Abuse
hopefully dont limit up so fast. can accumulate.
2020-06-01 17:31 | Report Abuse
LIMIT up tomorrow. operator gonna goreng. rumours of takeover.
2020-05-31 23:38 | Report Abuse
HLT shoot shoot shoot. Hopw to get into early bird tmr!
2020-05-30 16:23 | Report Abuse
pak tua believe hlt. gogogo hlt boom like adventa! pak tua never wrong
2020-05-30 16:10 | Report Abuse
add me to the group please paktua73@30k
2020-05-19 01:24 | Report Abuse
Tomorrow confirm gap up.. got chance queue higher d.. if hit above 90 cents possible to go back rm1.
2020-05-18 22:48 | Report Abuse
Alot of people stuck at rm 90 cents above. correction 2 days. good to accumulate. if naik, keep for 2 days. watch tomorrow. tomorrow boom keep 2 days, t+2 above rm 1 sell
2020-05-12 18:57 | Report Abuse
Terima kasih ats sharing yvonne. Nova good company. Net cash. Tak yah risau.
2020-05-12 18:57 | Report Abuse
follow by NOVA wellness. ikut sekali semua healthcare limit up besok
2020-05-12 18:36 | Report Abuse
semua alive ke! naik baru alive. jom HUAT skl.
Stock: [MI]: MI TECHNOVATION BERHAD
2024-05-19 21:26 | Report Abuse
https://www.semiconductor-digest.com/key-measures-of-global-semiconductor-manufacturing-industry-strength-improve-in-q1-2024-semi-reports/
recovery is here. don't wait